Jan 18, 2024
Surrozen Provides Corporate Update on Clinical Programs
Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043 - Completed enrollment for the Phase 1a clinical trial in chronic liver disease patients and healthy volunteers - Expect to announce Phase 1a safety and